UNIVERSITY OF MICHIGAN
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1817-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.umich.edu
Clinical Trials
1.4k
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1191 trials with phase data)• Click on a phase to view related trials
Mobile Platform for Optimizing Wellness and Engagement in Recovery
- Conditions
- Opioid Agonist TreatmentAlcohol Use DisorderOpioid Use Disorder
- First Posted Date
- 2025-09-17
- Last Posted Date
- 2025-09-17
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 50
- Registration Number
- NCT07178990
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
Efficacy of a Wearable Noninvasive Neuromodulation Device
- Conditions
- Spinal Cord Injuries
- First Posted Date
- 2025-09-12
- Last Posted Date
- 2025-09-12
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 100
- Registration Number
- NCT07171489
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
Rectal Evacuation Disorders and Straining-associated Symptoms in Bleeding Hemorrhoids
- Conditions
- Bleeding HemorrhoidsRectal Evacuation Disorders
- First Posted Date
- 2025-09-09
- Last Posted Date
- 2025-09-09
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 100
- Registration Number
- NCT07161765
- Locations
- 🇺🇸
University of MIchigan, Ann Arbor, Michigan, United States
Supporting Care Partners' Well-Being With Artificial Intelligence (AI) Chatbots
- Conditions
- Caregivers
- First Posted Date
- 2025-08-28
- Last Posted Date
- 2025-08-28
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 30
- Registration Number
- NCT07145723
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
Microbial Colonization in Three Dimensional (3D) Printed Orthodontic Clear Aligners
- Conditions
- Orthodontic AlignerMicrobial Colonization
- First Posted Date
- 2025-08-27
- Last Posted Date
- 2025-08-27
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 30
- Registration Number
- NCT07143370
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 285
- Next
News
First-in-Class Monoclonal Antibody Shows Promise Against Sepsis-Induced Immune Dysregulation
Researchers at University of Virginia and University of Michigan developed a humanized monoclonal antibody targeting citrullinated histone H3 to combat sepsis, which kills approximately 11 million people worldwide annually.
University of Michigan Develops At-Home Melanoma Detection Patch Using Microneedle Technology
Researchers at the University of Michigan have developed the ExoPatch, a silicone patch with star-shaped microneedles that can detect melanoma by capturing disease-specific exosomes from skin tissue.
Biomerica Appoints Scott Madel as Chief Commercial Officer to Drive inFoods IBS Test Commercialization
Biomerica has appointed Scott Madel as Chief Commercial Officer to accelerate commercialization of its inFoods IBS diagnostic test, bringing over 20 years of experience in laboratory testing and clinical diagnostics.
Courage Therapeutics Appoints Giovanni Ferrara as CEO to Advance Melanocortin-Targeted Obesity Treatments
Courage Therapeutics has appointed biopharma veteran Giovanni Ferrara as CEO following a significant investment from Arsenal Bridge Ventures in May.
Epcoritamab Demonstrates Durable 3-Year Remissions in Relapsed/Refractory Large B-Cell Lymphoma
Epcoritamab-bysp achieved durable complete responses in patients with relapsed/refractory large B-cell lymphoma, with 96% of complete responders at 2 years maintaining remission at 3 years.
Mayo Clinic Researchers Discover Drug Treatment to Triple Donor Heart Preservation Time
Mayo Clinic researchers identified that mineralocorticoid receptor proteins clump together during cold storage, causing cardiac damage through increased inflammation and cell death.
DT-109: Novel Glycine-Based Compound Shows Dual Efficacy Against Atherosclerosis and MASH
• University of Michigan researchers have demonstrated that DT-109, a glycine-based tripeptide, significantly reduces atherosclerotic plaque formation in nonhuman primates while inhibiting vascular calcification processes. • The compound, which previously showed efficacy in treating metabolic dysfunction-associated steatotic liver disease (MASH), represents a potential breakthrough as a dual-action therapy addressing both liver dysfunction and cardiovascular complications. • Unlike conventional treatments that primarily lower cholesterol, DT-109 targets underlying inflammatory pathways including NLRP3 inflammasome signaling, potentially addressing root causes of atherosclerosis rather than just managing symptoms.
Breakthrough T1D Invests $2.8 Million to Establish Joint Cardiorenal Center of Excellence for Type 1 Diabetes Research
Breakthrough T1D has awarded $2.8 million over three years to create the U-M-OHSU Cardiorenal Center of Excellence, expanding research on heart and kidney complications in type 1 diabetes patients.
Trump Administration Cancels $800 Million in LGBTQ Health Research Funding
The Trump administration has terminated 323 NIH grants worth $806 million focused on LGBTQ health research, affecting studies on HIV prevention, cancer, and mental health.
Loneliness Epidemic Shifts: Middle-Aged Americans More Isolated Than Seniors, New Research Reveals
One-third of Americans aged 50-80 report feeling lonely, with rates returning to pre-pandemic levels after peaking at 42% during COVID-19, according to University of Michigan research.